Squires Raynal C, Muehlbauer Stefan M, Brojatsch Jürgen
Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
J Biol Chem. 2007 Nov 23;282(47):34260-7. doi: 10.1074/jbc.M705687200. Epub 2007 Sep 17.
Activation of caspase-1 through the inflammasome protein Nalp1b controls anthrax lethal toxin (LT)-induced necrosis in murine macrophages. In this study we analyzed physiological changes controlled by caspase-1 in LT-treated murine macrophages. The caspase-1 inhibitor Boc-D-cmk blocked caspase-1 activity and membrane impairment in LT-treated cells. To determine the relationship between caspase-1 activation and membrane integrity, we added Boc-D-cmk to J774A.1 macrophages at different time points following LT exposure. Remarkably, Boc-D-cmk rescued LT-treated macrophages, even when added at the peak of caspase-1 activation. Late addition of the caspase-1 inhibitor reversed the losses of plasma membrane integrity and metabolic activity in these cells. Similar results were obtained with the proteasome inhibitor MG132, one of the most potent inhibitors of LT toxicity. LT-treated macrophages displaying evidence of membrane impairment recovered upon the addition of MG132, mirroring the Boc-D-cmk response. Strikingly, late addition of proteasome inhibitors also abrogated caspase-1 activity in LT-treated macrophages. Proteasomal control of caspase-1 activity and membrane impairment, however, was restricted to LT-induced cytolysis, because proteasome inhibitors did not block caspase-1 activation and cell death triggered by lipopolysaccharide and nigericin. Our findings indicate that proteasome inhibitors do not target caspase-1 directly but instead control an upstream event in LT-treated macrophages leading to caspase-1 activation. Taken together, caspase-1-mediated necrosis appears to be tightly controlled and differentially regulated by proteasomes depending on the source of caspase-1 induction.
通过炎性小体蛋白Nalp1b激活半胱天冬酶-1可控制炭疽致死毒素(LT)诱导的小鼠巨噬细胞坏死。在本研究中,我们分析了半胱天冬酶-1在经LT处理的小鼠巨噬细胞中所控制的生理变化。半胱天冬酶-1抑制剂Boc-D-cmk可阻断经LT处理细胞中的半胱天冬酶-1活性和膜损伤。为了确定半胱天冬酶-1激活与膜完整性之间的关系,我们在LT暴露后的不同时间点向J774A.1巨噬细胞中添加Boc-D-cmk。值得注意的是,即使在半胱天冬酶-1激活的高峰期添加Boc-D-cmk,也能挽救经LT处理的巨噬细胞。后期添加半胱天冬酶-1抑制剂可逆转这些细胞中质膜完整性和代谢活性的丧失。蛋白酶体抑制剂MG132(最有效的LT毒性抑制剂之一)也得到了类似结果。显示有膜损伤迹象的经LT处理的巨噬细胞在添加MG132后恢复,这与Boc-D-cmk的反应相似。令人惊讶的是,后期添加蛋白酶体抑制剂也能消除经LT处理的巨噬细胞中的半胱天冬酶-1活性。然而,蛋白酶体对半胱天冬酶-1活性和膜损伤的控制仅限于LT诱导的细胞溶解,因为蛋白酶体抑制剂不会阻断脂多糖和尼日利亚菌素触发的半胱天冬酶-1激活和细胞死亡。我们的研究结果表明,蛋白酶体抑制剂并非直接靶向半胱天冬酶-1,而是控制经LT处理的巨噬细胞中导致半胱天冬酶-1激活的上游事件。综上所述,半胱天冬酶-1介导的坏死似乎受到蛋白酶体的严格控制,并根据半胱天冬酶-1诱导的来源进行差异调节。